Silo Pharma Announces Expansion of Intellectual Property Portfolio
February 02 2023 - 7:50AM
Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a
developmental stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research, today announced
that the U.S. Patent and Trademark Office (USPTO) today issued U.S.
Patent 11,491,120, titled “Pharmacological Prophylactics Against
Stress-Induced Affective Disorders In Females.” The allowed claims
protect the use of portfolio drug SPC-15 in a method of treating
stress-induced affective disorders including anxiety and
post-traumatic stress disorder (PTSD).
“After a comprehensive review by USPTO, we are pleased with the
scope of the granted claims offering further protection for our
novel SPC-15 technology and its market potential for anxiety, PTSD,
and related disorders,” said Eric Weisblum, Chief Executive
Officer
Through its commercial evaluation license agreement with
Columbia University, the Company holds an option to license certain
assets currently under development by Columbia, including potential
treatments for stress-induced affective disorders and Alzheimer’s
disease.
SPC-15 is a targeted prophylactic using ketamine compositions as
a method of treatment and prevention for stress-induced affective
disorders including PTSD. The treatment predicts levels of severity
or progression of such disorders and their metabolomic biomarkers’
response to pharmacological treatments.
With the patent announced today, the Company expands its
intellectual property and technology rights for the treatment of
rare diseases,
About Silo Pharma Silo Pharma. Inc. is a
development-stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research for people
suffering from indications such as PTSD, Alzheimer’s disease, and
other rare neurological disorders. Silo’s mission is to identify
assets to license and fund the research which we believe will be
transformative to the well-being of patients and the healthcare
industry. For more information, visit www.silopharma.com.
Forward-Looking Statements All statements other than
statements of historical fact in this announcement are
forward-looking statements that involve known and unknown risks and
uncertainties and are based on current expectations and projections
about future events and financial trends that the Company believes
may affect its financial condition, results of operations, business
strategy, and financial needs. Investors can identify these
forward-looking statements by words or phrases such as "may,"
"will," "expect," "anticipate," "aim," "estimate," "intend,"
"plan," "believe," "potential," "continue," "is/are likely to" or
other similar expressions. The Company undertakes no obligation to
update forward-looking statements to reflect subsequent occurring
events or circumstances, or changes in its expectations, except as
may be required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review other factors that may affect its
future results in the Company's filings with the SEC.
Contact 800-705-0120investors@silopharma.com
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From Jul 2023 to Jul 2024